Drug Trial Radar · NCT02294058
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Last checked: Nov 20, 2026Latest source record: Nov 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,346
Actual
Start
Dec 3, 2014
Primary completion
Dec 22, 2016
Study completion Dec 22, 2016
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Conditions
- Multiple Sclerosis
Interventions
OzanimodDrug
Capsules for oral administration once a day
Interferon beta-1aDrug
Administered by intramuscular injection once a week
Placebo to ozanimodDrug
Matching placebo capsules administered orally once a day
Placebo to interferon beta-1aDrug
Placebo intramuscular injection once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Annualized Relapse Rate (ARR) During the Treatment PeriodTime frame: 12 months
Locations
224 sites in 25 countries. Site status is shown where the registry gives one.
Xenosciences Inc
Phoenix, Arizona
St Josephs Hospital and Medical Center
Phoenix, Arizona
Northwest Neuro Specialists PLLC
Tucson, Arizona
Alta Bates Summit Medical Center
Berkeley, California
Collaborative Neuroscience Network Inc
Long Beach, California
University of California Davis Medical Center
Sacramento, California
Multiple Sclerosis Center at UCSF
San Francisco, California
Denver Neurological Clinic
Denver, Colorado
Neurology Associates PA
Maitland, Florida
Neurology Associates of Ormond Beach
Ormond Beach, Florida
Infinity Clinical Research LLC
Pompano Beach, Florida
Neurostudies Inc
Port Charlotte, Florida
Roskamp Institute
Sarasota, Florida
Axiom Clinical Research of Florida
Tampa, Florida
Meridien Research
Tampa, Florida
West Georgia Sleep Disorder Center and Neurology Associates
Douglasville, Georgia
Consultants In Neurology
Northbrook, Illinois
University of Kansas Medical Center
Kansas City, Kansas
MidAmerica Neuroscience Research Foundation
Lenexa, Kansas
Associates In Neurology
Lexington, Kentucky
Norton Healthcare
Louisville, Kentucky
Henry Ford Health System
Detroit, Michigan
Michigan State University
East Lansing, Michigan
Minneapolis Clinic of Neurology
Golden Valley, Minnesota
Washington University
St Louis, Missouri
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada
Neurology Specialists of Monmouth County PA
West Long Branch, New Jersey
Neuro Medical Care Associates PLLC
Johnson City, New York
Raleigh Neurology Associates PA
Raleigh, North Carolina
Neurology and Neuroscience Associates Inc.
Akron, Ohio
Neurological Research Institute Inc
Columbus, Ohio
Providence Multiple Sclerosis Center
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Hope Neurology MS Center
Knoxville, Tennessee
University of Texas Health Science Center at Houston
Houston, Texas
Bhupesh Dihenia MD PA
Lubbock, Texas
EvergreenHealth
Kirkland, Washington
The Polyclinic
Seattle, Washington
Neurology of Neurosurgery Associates of Tacoma
Tacoma, Washington
Center for Neurological Disorders
Milwaukee, Wisconsin
Showing 40 of 224 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.